ADAM8, ADAM9, ADAM12, ADAM15 and ADAM17 were identified as promising biomarkers for the assessment of CRC progression and proved to be prognostic indicators for patients' survival. This evidence concerns the gene ADAM15 and colorectal carcinoma.